Abstract:Among the best-established causal risk factors for cardiovascular disease is the blood concentration of low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), an antagonist to the LDL receptor, has emerged as a promising therapeutic target for the prevention of coronary heart disease. Current PCSK9 inhibitors are administered via subcutaneous injection, and their effects are short-lived. An alternative “one-and-done” strategy using genome editing to disrupt PCSK9 at the DNA level has been demonstrated in preclinical animal models, including non-human primates. However, concerns about the permanence and irreversibility of the genomic changes have been raised and might limit the acceptance of the therapies. Recently, a set of CRISPR-based epigenome editing tools, CRISPRoff and CRISPRon, were reported to regulate gene expression via site-directed methylation and demethylation of gene promoters, respectively. We hypothesized that these epigenome editing tools could durably and reversibly induce methylation changes in the PCSK9 promoter and thereby modulate its expression. We first screened CRISPRoff guide RNAs (gRNAs) targeting the PCSK9 promoter, individually and in dual combinations, for their ability to reduce PCSK9 expression in the human HuH-7 hepatoma cell line. We then performed long-term experiments with the lead candidate gRNAs. We found that these CRISPRoff gRNAs induced profound increases in methylation at CpG dinucleotides in the PCSK9 promoter, with up to 80% decreases in PCSK9 expression. These methylation increases and gene expression decreases have endured through >56 cell divisions so far, with only mild attenuation over time. Using the same gRNAs with CRISPRon in cells previously treated with CRISPRoff, we observed moderate decreases in methylation and increases in PCSK9 expression. Having established these effects in vitro , we are similarly assessing the durability and reversibility of epigenome editing using the lead gRNAs in a PCSK9 -humanized mouse model. Overall, this work provides a proof of concept of precise gene regulation via methylation and demethylation and suggests a potential new therapeutic approach for protection against coronary heart disease.

CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

Therapeutic Gene Editing in Dyslipidemias

Abstract 27: Therapeutic Targeting of Human Lipid Genes With in vivo CRISPR-Cas9 Genome Editing

Gene editing for dyslipidemias: New tools to "cut" lipids

Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas9

Abstract 125: Reversible Epigenome Editing Of PCSK9 As A Therapeutic Strategy

Gene editing in common cardiovascular diseases

Triple‐Targeting Delivery of CRISPR/Cas9 to Reduce the Risk of Cardiovascular Diseases

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond

CRISPR/CAS9: A promising approach for the research and treatment of cardiovascular diseases

PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection

Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia

The Use of CRISPR-Cas9 Genetic Technology in Cardiovascular Disease: A Comprehensive Review of Current Progress and Future Prospective

Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9

First-in-human gene editing for lipid lowering: the initial results

The potential application and challenge of powerful CRISPR/Cas9 system in cardiovascular research

Gene Editing Therapy for Cardiovascular Diseases

A new era of clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 gene editing technology in cardiovascular diseases: Opportunities, challenges, and perspectives

CRISPR Interference–Potential Application in Retinal Disease

CRISPR-Cas12a Delivery by DNA-mediated Bioresponsive Editing for Cholesterol Regulation